Literature DB >> 20123473

Psychosocial aspects of PKU: hidden disabilities--a review.

J K Gentile1, A E Ten Hoedt, A M Bosch.   

Abstract

Phenylketonuria (PKU) is an inborn error of metabolism, and its detrimental effects on neurocognitive functioning have been well studied. Early detection and treatment of PKU prevent the severe consequences of this disorder. However, even early- and well-treated patients experience hidden disabilities, including subtle deficits in executive functioning, mild reductions in mental processing speed, social difficulties, and emotional problems that may remain unnoticed for years. Poor executive function (EF) may impact treatment adherence and may lead to psychosocial deficits that are not always visible. These psychosocial aspects include social difficulties and psychosocial problems, such as forming interpersonal relationships, achieving autonomy, attaining educational goals, and having healthy emotional development. Studies report EF deficits in children and adults with early-treated PKU, which contribute significantly to the hidden disabilities in this population. In adults, hidden disabilities affect job performance and social relationships as a result of residual attention deficits, poor EF (e.g., planning, organizing), and reduced processing speed. An indirect relationship also exists between quality of life and EF impairment. In the absence of overt psychiatric symptoms, low level depressive or anxious symptom may be present. The interaction between the neurocognitive deficits and psychiatric symptoms puts this population of patients at significant risk for experiencing hidden disability. PKU is a disorder in which a less than optimal psychosocial outcome arises from the cumulative impact of relatively mild symptoms. The key to reducing risks associated with PKU is metabolic control throughout life. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20123473     DOI: 10.1016/j.ymgme.2009.10.183

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  32 in total

Review 1.  Phenylketonuria: a 21st century perspective.

Authors:  Francjan J van Spronsen
Journal:  Nat Rev Endocrinol       Date:  2010-09       Impact factor: 43.330

2.  Impact of quaternary structure dynamics on allosteric drug discovery.

Authors:  Eileen K Jaffe
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

3.  Expanding research to provide an evidence base for nutritional interventions for the management of inborn errors of metabolism.

Authors:  Kathryn M Camp; Michele A Lloyd-Puryear; Lynne Yao; Stephen C Groft; Melissa A Parisi; Andrew Mulberg; Rashmi Gopal-Srivastava; Stephen Cederbaum; Gregory M Enns; Abby G Ershow; Dianne M Frazier; John Gohagan; Cary Harding; R Rodney Howell; Karen Regan; Peter W Stacpoole; Charles Venditti; Jerry Vockley; Michael Watson; Paul M Coates
Journal:  Mol Genet Metab       Date:  2013-05-23       Impact factor: 4.797

4.  Developmental Trajectories of Executive and Verbal Processes in Children with Phenylketonuria.

Authors:  Zoë W Hawks; Michael J Strube; Neco X Johnson; Dorothy K Grange; Desirée A White
Journal:  Dev Neuropsychol       Date:  2018-02-12       Impact factor: 2.253

5.  Sapropterin hydrochloride: enzyme enhancement therapy for phenylketonuria.

Authors:  Robin Lachmann
Journal:  Ther Adv Endocrinol Metab       Date:  2011-06       Impact factor: 3.565

6.  A new model for allosteric regulation of phenylalanine hydroxylase: implications for disease and therapeutics.

Authors:  Eileen K Jaffe; Linda Stith; Sarah H Lawrence; Mark Andrake; Roland L Dunbrack
Journal:  Arch Biochem Biophys       Date:  2013-01-11       Impact factor: 4.013

Review 7.  Up to date knowledge on different treatment strategies for phenylketonuria.

Authors:  Amaya Bélanger-Quintana; Alberto Burlina; Cary O Harding; Ania C Muntau
Journal:  Mol Genet Metab       Date:  2011-08-16       Impact factor: 4.797

8.  Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria.

Authors:  Krista S Viau; Heidi J Wengreen; Sharon L Ernst; Nancy L Cantor; Larissa V Furtado; Nicola Longo
Journal:  J Inherit Metab Dis       Date:  2011-05-10       Impact factor: 4.982

9.  Prolonged exposure to high and variable phenylalanine levels over the lifetime predicts brain white matter integrity in children with phenylketonuria.

Authors:  Anna Hood; Jo Ann V Antenor-Dorsey; Jerrel Rutlin; Tamara Hershey; Joshua S Shimony; Robert C McKinstry; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desiree A White
Journal:  Mol Genet Metab       Date:  2014-11-13       Impact factor: 4.797

Review 10.  The neuropsychiatry of inborn errors of metabolism.

Authors:  Mark Walterfang; Olivier Bonnot; Ramon Mocellin; Dennis Velakoulis
Journal:  J Inherit Metab Dis       Date:  2013-05-23       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.